Patient characteristics of patient with final BM cohort
| Characteristics | BC | NSCLC | PC | |||
| N | 559 | 894 | 1013 | |||
| Follow-up: median days (Q1–Q3) | 458 (128–933) | 87 (37–205) | 682 (357) | |||
| Age at BM diagnosis, median (Q1–Q3) | 65 (52–76) | 69 (62–77) | 75 (62–77) | |||
| Stage IV at primary cancer diagnosis | 30% | 86% | 72% | |||
| History of SRE at BM diagnosis | ||||||
| In the 56-day pre-BM-diagnosis period | 35% | 94% | 25% | |||
| Less than 16 days before BM diagnosis | 1% | 3% | 1% | |||
| Within 16–32 days before BM diagnosis | 3% | 8% | 5% | |||
| BTA | No BTA | BTA | No BTA | BTA | No BTA | |
| N | 294 | 265 | 117 | 777 | 121 | 892 |
| Sex–female | 100% | 100% | 45% | 45% | 0% | 0% |
| Primary cancer stage IV | 29% | 30% | 85% | 86% | 74% | 71% |
| CRPC diagnosis | #* | #* | #* | #* | 82% | 56% |
| At BM diagnosis | # | # | # | # | #* | #* |
| ECOG present | 64% | 39% | 86% | 82% | 30% | 19% |
| ECOG 0–2 | 94% | 81% | 67% | 49% | 27% | 18% |
| eGFR† median (Q1–Q3) | 81 (67–90) | 83 (60–90) | 90 (72–90) | 86 (66–90) | 82 (65–90) | 73 (57–90) |
| eGFR† <60 | 15% | 22% | 14% | 17% | 17% | 26% |
| Hypercalcaemia‡ classification at BM diagnosis | ||||||
| <2.75 mmol/L | 90.51% | 88.33% | 82.20% | 94.27% | 75.21% | 71.65% |
| Mild | 3.05% | # | 6.78% | 2.00% | 0.00% | # |
| Moderate | # | # | 6.78% | # | 0.00% | # |
| Severe | # | 0.00% | # | # | 0.00% | 0.00% |
| Missing/Unknown | # | 8.95% | # | 2.40% | 24.79% | 27.76% |
| Renal disease | ||||||
| Yes | # | 3.4% | # | 3.6% | 0.8% | 3.8% |
| Missing | 70.4% | 56.6% | 23.1% | 21.5% | 57.0% | 47.2% |
| CCI | ||||||
| 0 | 21.4% | 31.3% | 57.3% | 51.1% | 33.1% | 39.4% |
| 1 | 5.4% | 4.2% | 14.5% | 16.6% | 4.1% | 5.9% |
| 2 | # | 4.9% | # | 6.8% | 5.0% | 4.9% |
| 3+ | # | 3.0% | # | 4.0% | 0.8% | 2.6% |
| Missing | 70.4% | 56.6% | 23.1% | 21.5% | 57.0% | 47.2% |
| Oestrogen receptor status | ||||||
| Positive | 84.4% | 72.1% | # | # | # | # |
| Missing | # | 3.0% | ||||
| Progesterone receptor status | ||||||
| Positive | 65.0% | 55.1% | # | # | # | # |
| Missing | 6.1% | 6.4% | ||||
| HR/HER2 status | ||||||
| HR–/HER2– | 10.0% | 17.0% | # | # | # | # |
| HR–/HER2+ | 3.4% | 6.8% | # | # | # | # |
| HR+/HER2– | 58.2% | 46.4% | # | # | # | # |
| HR+/HER2+ | 5.8% | 5.3% | # | # | # | # |
| Missing | 22.8% | 24.5% | # | # | # | # |
| EGFR mutation | ||||||
| Pathogenic | # | # | 9.4% | 5.2% | # | # |
| Wildtype | # | # | 45.3% | 29.6% | # | # |
| Missing | # | # | 45.3% | 65.3% | # | # |
| ALK mutation | ||||||
| Pathogenic | # | # | # | 2.2% | # | # |
| Wildtype | # | # | 41.0% | 21.8% | # | # |
| Missing | # | # | 55.6% | 76.1% | # | # |
| PD-L1 mutation | ||||||
| High (50%) | # | # | # | 4.1% | # | # |
| Intermediate (1–49%) | # | # | 10.3% | # | # | # |
| Low (<1%) | # | # | 13.7% | 5.0% | # | # |
| Not done | # | # | 25.6% | 19.1% | # | # |
| missing | # | # | 44.4% | 68.5% | # | # |
| Histopathological stage | ||||||
| Squamous-cell carcinoma | # | # | 23.1% | 15.6% | # | # |
| Other specified NSCLC | # | # | # | 2.7% | # | # |
| NSCLC NOS | # | # | 12% | 16.6% | # | # |
| Non-squamous NSCLC | # | # | 49.6% | 39.6% | # | # |
| missing | # | # | 11.1% | 25.5% | # | # |
| Therapy before BTA administration‡ | ||||||
| None | 12.9% | 10.6% | 59.8% | 68.5% | 63.6% | 72.9% |
| RT | # | #* | # | 2.3% | 8.3% | 6.1% |
| RT and surgery | 15.0% | 11.7% | # | 1.9% | 5.8% | 4.2% |
| SACT¶ | # | 0 | 7.7% | 2.3% | # | #* |
| SACT and RT | # | 0 | # | 2.1% | # | 0.8% |
| SACT and surgery | 11.9% | 7.9% | # | 3.5% | # | # |
| SACT, RT and surgery | 32.7% | 33.2% | 6.8% | 3.2% | # | # |
| Surgery | 25.9% | 34.7% | 13.7% | 16.2% | 16.5% | 14.6% |
*#Means <6 patients.
†eGFR units: mL/min/1.73 m2).
‡The level of hypercalcaemia was based on the following serum calcium levels (mmol/L): mild 2.75–3.00; moderate 3.00–3.40; severe 3.40+.
§The time period for these therapies includes the time from primary cancer to BM diagnosis.
¶SACT was cancer-specific and included chemotherapy, endocrine therapy and targeted therapy.
ALK, anaplastic lymphoma kinase; BM, bone metastasis; BTA, bone-targeting agent; CCI, Charlson Comorbidity Index; CRPC, castration-resistant prostate cancer; ECOG, Eastern Cooperative Oncology Group; eGFR, estimated glomerular filtration rate; HER, human epidermal growth factor receptor; HR, hormone receptor; NA, not available; NOS, non-otherwise specified; NSCLC, non-small cell lung cancer; PD-L1, programmed cell death receptor ligand-1; RT, radiotherapy; SACT, systemic anticancer therapy.